Circulating tumour cells and cancer stem cells: A role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 129-143

  Scatena, Roberto ^a   Bottoni, Patrizia ^a   Giardina, Bruno ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cancer stem cells; Circulating tumour cells; Circulating tumour stem cells; Migrating cancer stem cells; Oncoproteomics; Tumour markers

Indexed keywords

ALPHAVBETA6 INTEGRIN; ANTINEOPLASTIC AGENT; BETA CATENIN; CISPLATIN; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; NERVE CELL ADHESION MOLECULE; PERILLYL ALCOHOL; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG; VIMENTIN;

CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CELL SUBPOPULATION; CIRCULATING TUMOR CELL; CYTOLOGY; DISEASE ACTIVITY; DRUG MECHANISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION;

ANIMALS; ANTIGENS, NEOPLASM; BETA CATENIN; BIOLOGICAL MARKERS; CADHERINS; CELL DIFFERENTIATION; CELL SEPARATION; HUMANS; INTEGRINS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEOMICS; TRANSCRIPTION FACTORS; VIMENTIN;

EID: 84872187924     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.12.002     Document Type: Review

References (161)

1. Wang J.C.Y., Dick J.E. Cancer stem cells. Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology 2008, 135-143. Lippincott Williams & Wilkins, Philadelphia, PA, USA. 8th edition. V.T. DeVita, T.S. Lawrence, S.A. Rosenberg (Eds.).
2. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N. Engl. J. Med. 2006, 355:1253-1261.
3. Trumpp A., Wiestler O.D. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat. Clin. Pract. Oncol. 2008, 5:337-347.
4. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
5. Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J., Terzis A.J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat. Rev. Cancer 2005, 5:899-904.
6. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8:329-340.
7. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
8. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
9. Scatena R., Bottoni P., Pontoglio A., Giardina B. Cancer stem cells: the development of new cancer therapeutics. Expert Opin. Biol. Ther. 2011, 11:875-892.
10. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest. 2011, 121:3804-3809.
11. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
12. Scatena R. Cancer stem cells: a revisitation of the anaplasia concept. Advances in Cancer Stem Cell Biology 2012, 1-16. Springer, New York. R. Scatena, A. Mordente, B. Giardina (Eds.).
13. Scatena R., Bottoni P., Pontoglio A., Giardina B. The proteomics of cancer stem cells: potential clinical applications for innovative research in oncology. Proteomics Clin. Appl. 2011, 5:590-602.
14. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
15. Woodward W.A., Sulman E.P. Cancer stem cells: markers or biomarkers?. Cancer Metastasis Rev. 2008, 27:459-470.
16. Keysar S.B., Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 2010, 9:2450-2457.
17. Dou J., Gu N. Biomarkers of cancer stem cells. Advances in Cancer Stem Cell Biology 2012, 45-68. Springer, New York. R. Scatena, A. Mordente, B. Giardina (Eds.).
18. Lotem J., Sachs L. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 2006, 25:7663-7672.
19. Belton A., Gabrovsky A., Bae Y.K., Reeves R., Iacobuzio-Donahue C., Huso D.L., Resar L.M. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 2012, 7:e30034.
20. Hwang W.L., Yang M.H., Tsai M.L., Lan H.Y., Su S.H., Chang S.C., et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011, 141:279-291.
21. Diamandis E.P., Pantel K., Scher H.I., Terstappen L., Lianidou E. Circulating cancer cells and their clinical applications. Clin. Chem. 2011, 57:1478-1484.
22. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 1869, 14:146.
23. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
24. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
25. Lin E.H., Jiang Y., Deng Y., Lapsiwala R., Lin T., Blau C.A. Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: "seed and soil" theory revisited. Gastrointest. Cancer Res. 2008, 2:169-174.
26. Ewing J. Neoplastic Diseases 1928, W. B. Saunders, Philadelphia.
27. Roberts S., Watne A., McGrath R. Technique and results of isolation of cancer cells from the circulating blood. Am. Med. Assoc. Arch. Surg. 1958, 76:334-346.
28. Long L., Jonasson O., Roberts S., McGrath R., McGrew E., Cole W.H. Cancer cells in blood. Results of a simplified isolation technique. Arch. Surg. 1960, 80:910-919.
29. Punnoose E.A., Atwal S.K., Spoerke J.M., Savage H., Pandita A., Yeh R.F., et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010, 5:e12517.
30. Lianidou E.S., Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem. 2011, 57:1242-1255.
31. Raimondi C., Gradilone A., Naso A.G., Vincenzi B., Petracca A., Nicolazzo C., et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 2011, 130:449-455.
32. Riethdorf S., Wikman H., Pantel K. Biological relevance of disseminated tumor cells in cancer patients. Int. J. Cancer 2008, 123:1991-2006.
33. Riethdorf S., Pantel K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 2008, 75:140-148.
34. Iinuma H., Okinaga K., Egami H., Mimori K., Hayashi N., Nishida K., et al. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int. J. Oncol. 2006, 28:297-306.
35. Peach G., Kim C., Zacharakis E., Purkayastha S., Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br. J. Cancer 2010, 102:1327-1334.
36. Yu M., Stott S., Toner M., Maheswaran S., Haber D.A. Circulating tumor cells: approaches to isolation and characterization. J. Cell Biol. 2011, 192:373-382.
37. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
38. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
39. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
40. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
41. Gerges N., Rak J., Jabado N. New technologies for the detection of circulating tumour cells. Br. Med. Bull. 2010, 94:49-64.
42. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massagué J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
43. Hofman V., Ilie M.I., Long E., Selva E., Bonnetaud C., Molina T., et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small cell lung carcinoma: comparison of the efficacy of the Cell Search assay and the isolation by size of epithelial tumor cell method. Int. J. Cancer 2010, 129:1651-1660.
44. Farace F., Massard C., Vimond N., Drusch F., Jacques N., Billiot F., et al. A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer 2011, 105:847-853.
45. Khoja L., Backen A., Sloane R., Menasce L., Ryder D., Krebs M., et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br. J. Cancer 2012, 106:508-516.
46. Hou J.M., Greystoke A., Lancashire L., Cummings J., Ward T., Board R., et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 2009, 175:808-816.
47. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11:R46.
48. Theodoropoulos P.A., Polioudaki H., Agelaki S., Kallergi G., Saridaki Z., Mavroudis D., Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010, 288:99-106.
49. Kasimir-Bauer S., Hoffmann O., Wallwiener D., Kimmig R., Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012, 14:R15.
50. Sun Y.F., Yang X.R., Zhou J., Qiu S.J., Fan J., Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J. Cancer Res. Clin. Oncol. 2011, 137:1151-1173.
51. Idowu M.O., Kmieciak M., Dumur C., Burton R.S., Grimes M.M., Powers C.N., Manjili M.H. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 2012, 43:364-373.
52. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
53. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077.
54. Di Palma S., Stange D., van de Wetering M., Clevers H., Heck A.J., Mohammed S. Highly sensitive proteome analysis of FACS-sorted adult colon stem cells. J. Proteome Res. 2011, 10:3814-3819.
55. Roulhac P.L., Ward J.M., Thompson J.W., Soderblom E.J., Silva M., Moseley M.A., Jarvis E.D. Microproteomics: quantitative proteomic profiling of small numbers of laser-captured cells. Cold Spring Harb. Protoc. 2011, 1. 10.1101/pdb.prot5573.
56. Scatena R., Bottoni P., Giardina B. Modulation of cancer cell line differentiation: a neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. Proteomics Clin. Appl. 2008, 2:229-237.
57. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark. 2007, 3:245-250.
58. Navakauskiene R., Treigyte G., Gineitis A., Magnusson K.E. Identification of apoptotic tyrosine-phosphorylatedproteins after etoposide or retinoic acid treatment. Proteomics 2004, 4:1029-1041.
59. Bottoni P., Giardina B., Vitali A., Boninsegna A., Scatena R. A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line. Biochim. Biophys. Acta 2009, 1794:615-626.
60. Warrel R.P. Cancer: Principles and Practice of Oncology 2001, 489-494. J. B. Lippincott Company, Philadelphia. V.T. De Vita, S. Hellmann, S.A. Rosenberg (Eds.).
61. Calleja E.M., Warrell R.P. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Curr. Oncol. Rep. 2000, 2:519-523.
62. Nomura T., Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Invest. 2005, 52:1-9.
63. Pauli C., Münz M., Kieu C., Mack B., Breinl P., Wollenberg B., et al. Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett. 2003, 193:25-32.
64. Bartkowiak K., Effenberger K.E., Harder S., Andreas A., Buck F., Peter-Katalinic J., et al. Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J. Proteome Res. 2010, 9:3158-3168.
65. Bhattacharya S., Mathew G., Ruban E., Epstein D.P., Krusche A., Hillert R., et al. Toponome imaging system: in situ protein network mapping in normal and cancerous colon from the same patient reveals more than five-thousand cancer specific protein clusters and their subcellular annotation by using a three symbol code. J. Proteome Res. 2010, 9:6112-6125.
66. Halvey P.J., Zhang B., Coffey R.J., Liebler D.C., Slebos R.J. Proteomic consequences of a single gene mutation in a colorectal cancer model. J. Proteome Res. 2012, 11:1184-1195.
67. Fang D.D., Kim Y.J., Lee C.N., Aggarwal S., McKinnon K., Mesmer D., et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br. J. Cancer 2010, 102:1265-1275.
68. Yen L., Cao Z., Wu X., Ingalla E.R., Baron C., Young L.J., et al. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res. 2006, 66:11279-11286.
69. Hermiston M.L., Wong M.H., Gordon J.I. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev. 1996, 10:985-996.
70. Chu Y.S., Eder O., Thomas W.A., Simcha I., Pincet F., BenZe'ev A., et al. Prototypical type I E-cadherin and type II cadherin-7 mediate very distinct adhesiveness through their extracellular domains. J. Biol. Chem. 2006, 281:2901-2910.
71. Berx G., van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol. 2009, 1:a003129.
72. Martinez-Rico C., Pincet F., Thiery J.P., Dufour S. Integrins stimulate E-cadherin-mediated intercellular adhesion by regulating Src-kinase activation and actomyosin contractility. J. Cell Sci. 2010, 123:712-722.
73. Velpula K.K., Dasari V.R., Tsung A.J., Dinh D.H., Rao J.S. Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget 2011, 2:1028-1042.
74. Radisky D.C., LaBarge M.A. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008, 2:511-512.
75. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
76. Morel A.P., Lièvre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
77. Eastham A.M., Spencer H., Soncin F., Ritson S., Merry C.L., Stern P.L., Ward C.M. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res. 2007, 67:11254-11262.
78. Ullmann U., In't Veld P., Gilles C., Sermon K., De Rycke M., Van de Velde H., et al. Epithelial-mesenchymal transition process in human embryonic stem cells cultured in feeder-free conditions. Mol. Hum. Reprod. 2007, 13:21-32.
79. Armstrong A.J., Marengo M.S., Oltean S., Kemeny G., Bitting R.L., Turnbull J.D., et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 2011, 9:997-1007.
80. Garcia J., Faca V., Jarzembowski J., Zhang Q., Park J., Hanash S. Comprehensive profiling of the cell surface proteome of Sy5Y neuroblastoma cells yields asubset of proteins associated with tumor differentiation. J. Proteome Res. 2009, 8:3791-3796.
81. Sosa M.S., Girotti M.R., Salvatierra E., Prada F., de Olmo J.A., Gallango S.J., et al. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 2007, 7:4123-4134.
82. Yang J.A., Eddy Y., Pan A., Hategan I., Tabus Y., Wang Y., et al. Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol. Cell. Proteomics 2010, 9:2405-2413.
83. Fuchs E., Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu. Rev. Biochem. 1994, 63:345-382.
84. Katsumoto T., Mitsushima A., Kurimura T. The role of the vimentin intermediate filaments in rat 3Y1 cells elucidated by immunoelectron microscopy and computer-graphic reconstruction. Biol. Cell 1990, 68:139-146.
85. Lane B., Anderton B. Focus on filaments: embryology to pathology. Nature 1982, 298:706-707.
86. Hendrix M.J., Seftor E.A., Chu Y.W., Trevor K.T., Seftor R.E. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev. 1996, 15:507-525.
87. Gonzales M., Weksler B., Tsuruta D., Goldman R.D., Yoon K.J., Hopkinson S.B., et al. Structure and function of a vimentin-associated matrix adhesion in endothelial cells. Mol. Biol. Cell 2001, 12:85-100.
88. Ku N.O., Liao J., Omary M.B. Phosphorylation of human keratin 18 serine 33 regulates binding to 14-3-3 proteins. EMBO J. 1998, 17:1892-1906.
89. Eriksson J.E., He T., Trejo-Skalli A.V., Harmala-Brasken A.S., Hellman J., Chou Y.H., Goldman R.D. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J. Cell Sci. 2004, 117:919-932.
90. Vossenaar E.R., Radstake T.R., van der Heijden A., van Mansum M.A., Dieteren C., de Rooij D.J., et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 2004, 63:373-381.
91. Wang L., Zhang J., Banerjee S., Barnes L., Sajja V., et al. Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration. Oncotarget 2010, 1:620-627.
92. Farach A.M., Galileo D.S. O-GlcNAc modification of radial glial vimentin filaments in the developing chick brain. Brain Cell Biol. 2008, 36:191-202.
93. Chen W.D., Han Z.J., Skoletsky J., Olson J., Sah J., Myeroff L. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 2005, 97:1124-1132.
94. Shirahata A., Sakata M., Sakuraba K., Goto T., Mizukami H., Saito M., et al. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 2009, 29:279-281.
95. Kitamura Y.H., Shirahata A., Sakata M., Goto T., Mizukami H., Saito M.M., et al. Frequent methylation of Vimentin in well-differentiated gastric carcinoma. Anticancer Res. 2009, 29:2227-2230.
96. Costa V.L., Henrique R., Danielsen S.A., Duarte-Pereira S., Eknaes M., Skotheim R.I., et al. Three epigenetic biomarkers, GDF15, TMEFF2 and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res. 2010, 16:5842-5851.
97. Jung S., Yi L., Kim J., Jeong D., Oh T., Kim C.H., et al. The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer. Mol. Cells 2011, 31:405-411.
98. Singh S., Sadacharan S., Su S., Belldegrun A., Persad S., Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res. 2003, 63:2306-2311.
99. Vasko V., Espinosa A.V., Scouten W., He H., Auer H., Liyanarachchi S., et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2803-2808.
100. Craven R.A., Stanley A.J., Hanrahan S., Dods J., Unwin R., Totty N., et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006, 6:2853-2864.
101. Wu M., Bai X., Xu G., Wei J., Zhu T., Zhang Y., et al. Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression. Proteomics 2007, 7:1973-1983.
102. Wei J., Xu G., Wu M., Zhang Y., Li Q., Liu P., et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 2008, 28:327-334.
103. Dos Santos A., Court M., Thiers V., Sar S., Guettier C., Samuel D., et al. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol. Cell. Proteomics 2010, 9:1991-2004.
104. Pan T.L., Wang P.W., Huang C.C., Yeh C.T., Hu T.H., Yu J.S. Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells. J. Proteomics 2012, 75:4676-4692.
105. Roy L.D., Sahraei M., Subramani D.B., Besmer D., Nath S., Tinder T.L., et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011, 30:1449-1459.
106. Sun S., Poon R.T., Lee N.P., Yeung C., Chan K.L., Ng I.O., et al. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (< or = 2cm). J. Proteome Res. 2010, 9:1923-1930.
107. Mor-Vaknin N., Punturieri A., Sitwala K., Markovitz D.M. Vimentin is secreted by activated macrophages. Nat. Cell Biol. 2003, 5:59-63.
108. Garg A., Barnes P.F., Porgador A., Roy S., Wu S., Nanda J.S., et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J. Immunol. 2006, 177:6192-6198.
109. Chong W.P., Zhou J., Law H.K., Tu W., Lau Y.L. Natural killer cells become tolerogenic after interaction with apoptotic cells. Eur. J. Immunol. 2010, 40:1718-1727.
110. Srivastava B.I., Srivastava M.D. Expression of natural cytotoxicity receptors NKp30, NKp44, and NKp46 mRNAs and proteins by human hematopoietic and non-hematopoietic cells. Leuk. Res. 2006, 30:37-46.
111. Halfteck G.G., Elboim M., Gur C., Achdout H., Ghadially H., Mandelboim O. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J. Immunol. 2009, 182:2221-2230.
112. Lakshmikanth T., Burke S., Ali T.H., Kimpfler S., Ursini F., Ruggeri L., et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 2009, 119:1251-1263.
113. Glasner A., Ghadially H., Gur C., Stanietsky N., Tsukerman P., Enk J., Mandelboim O. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J. Immunol. 2012, 188:2509-2515.
114. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
115. Uchikado Y., Natsugoe S., Okumura H., Setoyama T., Matsumoto M., Ishigami S., Aikou T. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 2005, 11:1174-1180.
116. Latifi A., Abubaker K., Castrechini N., Ward A.C., Liongue C., Dobill F., et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem. 2011, 112:2850-2864.
117. Satelli A., Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 2011, 68:3033-3046.
118. Bandyopadhyay A., Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr. Drug Targets 2009, 10:645-652.
119. Kong L., Sun J.W., Zhang C.H. The expression of integrinανβ6 and MMP-9 in gastric cancer and the correlation with clinicopathologic characteristic. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011, 27:92-94.
120. Patsenker E., Wilkens L., Banz V., Osterreicher C.H., Weimann R., Eisele S., et al. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J. Hepatol. 2010, 52:362-369.
121. Dang D., Ramos D.M. Identification of {alpha}v{beta}6-positive stem cells in oral squamous cell carcinoma. Anticancer Res. 2009, 29:2043-2049.
122. Morgan M.R., Jazayeri M., Ramsay A.G., Thomas G.J., Boulanger M.J., Hart I.R., Marshall J.F. Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion. Oncogene 2011, 30:1422-1435.
123. Mustafa D.A., Dekker L.J., Stingl C., Kremer A., Stoop M., Sillevis Smitt P.A., et al. A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma. Mol. Cell. Proteomics 2012, 11. M111.008466.
124. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
125. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32:577-595.
126. Patel S., Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop?. Cancer Cell 2008, 14:351-353.
127. Lee C.F., Griffiths S., Rodríguez-Suárez E., Pierce A., Unwin R.D., Jaworska E., et al. Assessment of downstream effectors of BCR/ABL protein tyrosine kinase using combined proteomic approaches. Proteomics 2010, 10:3321-3342.
128. Fischer Jde S., Liao L., Carvalho P.C., Barbosa V.C., Domont G.B., Carvalho Mda G., Yates J.R. Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol. J. Proteomics 2010, 73:1018-1027.
129. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol. Cancer 2010, 9:144.
130. Wulfkuhle J.D., Aquino J.A., Calvert V.S., Fishman D.A., Coukos G., Liotta L.A., Petricoin E.F. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003, 3:2085-2090.
131. Seke Etet P.F., Vecchio L., Bogne Kamga P., Nchiwan Nukenine E., Krampera M., Nwabo Kamdje A.H. Normal hematopoiesis and hematologic malignancies: role of canonical Wnt signaling pathway and stromal microenvironment. Biochim. Biophys. Acta 2012, 1835:1-10.
132. Ali N.A., Molloy M.P. Quantitative phosphoproteomics of transforming growth factor-β signaling in colon cancer cells. Proteomics 2011, 11:3390-3401.
133. Cho S.H., Park Y.S., Kim H.J., Kim C.H., Lim S.W., Huh J.W., et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int. J. Oncol. 2012, 41:211-218.
134. Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol. Biol. 2008, 468:5-15.
135. White B.D., Chien A.J., Dawson D.W. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 2012, 142:219-232.
136. Yao H., Ashihara E., Maekawa T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin. Ther. Targets 2011, 15:873-887.
137. Ge X., Wang X. Role of Wnt canonical pathway in hematological malignancies. J. Hematol. Oncol. 2010, 3:33.
138. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin. Cancer Res. 2010, 16:3153-3162.
139. Huang H., He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr. Opin. Cell Biol. 2008, 20:119-125.
140. Paul S., Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008, 55:165-176.
141. Herencia C., Martínez-Moreno J.M., Herrera C., Corrales F., Santiago-Mora R., Espejo I., et al. Nuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS One 2012, 7:e34656.
142. Abu-Remaileh M., Gerson A., Farago M., Nathan G., Alkalay I., Zins Rousso S., et al. Oct-3/4 regulates stem cell identity and cell fate decisions by modulating Wnt/β-catenin signaling. EMBO J. 2010, 29:3236-3248.
143. Zhang S., Wang X., Osunkoya A.O., Iqbal S., Wang Y., Chen Z., et al. EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene 2011, 30:4941-4952.
144. Cossais F., Wahlbuhl M., Kriesch J., Wegner M. SOX10 structure-function analysis in the chicken neural tube reveals important insights into its role in human neurocristopathies. Hum. Mol. Genet. 2010, 19:2409-2420.
145. Seong I., Min H.J., Lee J.H., Yeo C.Y., Kang D.M., Oh E.S., et al. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes. PLoS One 2012, 7:e31477.
146. Civenni G., Walter A., Kobert N., Mihic-Probst D., Zipser M., Belloni B., et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011, 71:3098-3109.
147. Bakos R.M., Maier T., Besch R., Mestel D.S., Ruzicka T., Sturm R.A., Berking C. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp. Dermatol. 2010, 19:e89-e94.
148. Wegwitz F., Kluth M.A., Mänz C., Otto B., Gruner K., Heinlein C., et al. Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system. PLoS One 2010, 5:e12103.
149. Morokuma J., Blackiston D., Adams D.S., Seebohm G., Trimmer B., Levin M. Modulation of potassium channel function confers a hyperproliferative invasive phenotype on embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16608-16613.
150. Schlierf B., Friedrich R.P., Roerig P., Felsberg J., Reifenberger G., Wegner M. Expression of SoxE and SoxD genes in human gliomas. Neuropathol. Appl. Neurobiol. 2007, 33:621-630.
151. Sato Y., Harada K., Itatsu K., Ikeda H., Kakuda Y., Shimomura S., et al. Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am. J. Pathol. 2010, 177:141-152.
152. Molina-Ortiz P., Villarejo A., Macpherson M., Santos V., Montes A., Souchelnytskyi S., et al. Characterization of the SNAG and SLUG domains of Snail2 in the repression of E-cadherin and EMT induction: modulation by serine 4 phosphorylation. PLoS One 2012, 7:e36132.
153. Christofori G. Snail1 links transcriptional control with epigenetic regulation. EMBO J. 2010, 29:1787-1789.
154. Hotz, Arndt M., Dullat S., Bhargava S., Buhr H.J., Hotz H.G. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin. Cancer Res. 2007, 13:4769-4776.
155. Larriba M.J., Casado-Vela J., Pendás-Franco N., Peña R., García de Herreros A., Berciano M.T., et al. Novel snail1 target proteins in human colon cancer identified by proteomic analysis. PLoS One 2010, 5:e10221.
156. Haslehurst A.M., Koti M., Dharsee M., Nuin P., Evans K., Geraci J., et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012, 12:91.
157. Zhu K., Chen L., Han X., Wang J., Wang J. Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells. Oncol. Rep. 2012, 27:1027-1034.
158. Yang M.H., Hsu D.S., Wang H.W., Wang H.J., Lan H.Y., Yang W.H., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 2010, 12:982-992.
159. Yang W.H., Lan H.Y., Huang C.H., Tai S.K., Tzeng C.H., Kao S.Y., et al. RAC1 activation mediates Twist1-induced cancer cell migration. Nat. Cell Biol. 2012, 14:366-374.
160. Kim H.D., Meyer A.S., Wagner J.P., Alford S.K., Wells A., Gertler F.B., Lauffenburger D.A. Signaling network state predicts twist-mediated effects on breast cell migration across diverse growth factor contexts. Mol. Cell. Proteomics 2011, 10:M111.
161. Kalluri R., Weinberg R.A. The basic of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.